Rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies

Summary

Rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies (MONDO:0016618) is a disease. A subtype of rheumatoid factor-negative juvenile idiopathic arthritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies
Mondo ID	MONDO:0016618
Orphanet	247861
GARD	0025082
Is cancer (heuristic)	no

Also known as: juvenile rheumatoid factor-negative polyarthritis without anti-nuclear antibodies · polyarthritis without rheumatoid factor without anti-nuclear antibodies · rheumatoid factor-negative JIA without anti-nuclear antibodies

Disease family

This is a subtype of rheumatoid factor-negative juvenile idiopathic arthritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › connective tissue disorder › rheumatic disorder › juvenile idiopathic arthritis › polyarticular juvenile idiopathic arthritis › rheumatoid factor-negative juvenile idiopathic arthritis › rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies

Related subtypes (1): rheumatoid factor-negative juvenile idiopathic arthritis with anti-nuclear antibodies

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.